Rogowski Law
  • Home
  • About
    • Pat Rogowski
    • Anna Sigmon
  • Ask Pat ®
  • Services / Industries
  • Press Releases
  • Contact
Select Page
GLP-1 Compounding: Compliance with FDA Rules Doesn’t Override Patent Rights

GLP-1 Compounding: Compliance with FDA Rules Doesn’t Override Patent Rights

Mar 17, 2026

Glucagon-like peptide-1 (GLP-1) receptor agonists are a global phenomenon. These drugs treat type 2 diabetes and obesity by mimicking gut hormones that suppress appetite and regulate blood sugar (1). Pharmaceutical giant Novo Nordisk dominates the FDA-approved GLP-1...

Recent Posts

  • GLP-1 Compounding: Compliance with FDA Rules Doesn’t Override Patent Rights
  • Pat Featured on Panel at The Randy J. Holland Joint Inns of Court
  • Is it OK for photos of my product to be downloadable from a stock photo website without my permission in the United States?
  • When Can Your Slogan Be Registered as a Trademark?
  • Supreme Court Holds First Amendment Doesn’t Give Unrestricted Right to Poop on Trademark Rights

Recent Comments

    Archives

    • March 2026
    • March 2025
    • January 2025
    • March 2024
    • June 2023
    • December 2022
    • September 2022
    • August 2022
    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • June 2021
    • November 2020
    • August 2020
    • June 2020
    • April 2020
    • February 2020
    • June 2019
    • May 2019
    • March 2019
    • February 2019
    • January 2019
    • October 2018
    • September 2018
    • August 2018
    • June 2018
    • April 2018
    • February 2018
    • November 2017
    • October 2017
    • August 2017
    • June 2017
    • March 2017

    Categories

    • AskPat®
    • Featured
    • Press Releases

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org